Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, ...
Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies ...
Propensity-matched analyses showed smokers had significantly higher risk across all studied ocular outcomes over 10 years, ...
Self-reported hearing impairment reduced the likelihood of achieving clinically meaningful functional improvement after ...
The early results from a phase II study on the use of the topotecan episcleral chemoplaque (Targeted Therapy Technologies LLC ...
Motugivatrep introduces first-in-class topical TRPV1 antagonism for DED, targeting corneal nociceptor-driven discomfort ...
Gabriel discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the ...
New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...
Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.
Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...
Uncorrected acuity at 36 months showed continuous range: monocular 20/20 distance and intermediate, 20/27 near; binocular ...
The FDA’s decision to extend the labeled duration of faricimab use in RVO beyond 6 months primarily reflects accumulated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results